Janis Naeve, Director
Amgen Ventures
Dr. Naeve joined Amgen in 2005 as a Director in the Company's corporate venture capital fund. She directs the fund's investment in early-stage biotechnology companies focused on discovering and developing human therapeutics. From 2002 to 2005, Dr. Naeve was director of Corporate Development at X-Ceptor Therapeutics which was acquired by Exelixis. Prior to this she was director of Business Development at Aurora Biosciences where she led transactions for the ion channel technology business unit and managed the collaborations with Pfizer, Merck, Lilly and Bristol Myers-Squibb. Dr. Naeve holds a Ph.D. in Pathology from University of Southern California and completed a post-doctoral fellowship at the California Institute of Technology.